BORTEZOMIB ADVANCED MECHANISMS OF ACTION IN MULTIPLE MYELOMA, SOLID AND LIQUID TUMORS ALONG WITH ITS NOVEL THERAPEUTIC APPLICATIONS

Mohammad Alwahsh, Joviana Farhat, Shahd Talhouni, Lama Hamadneh, Roland Hergenröder

    Research output: Contribution to journalReview articlepeer-review

    4 Scopus citations

    Abstract

    Bortezomib (BTZ) is a first-in-class reversible and selective proteasome inhibitor. It inhibits the ubiquitin proteasome pathway that leads to the degradation of many intracellular proteins. Initially, BTZ was FDA approved for the treatment of refractory or relapsed multiple myeloma (MM) in 2003. Later, its usage was approved for patients with previously untreated MM. In 2006, BTZ was approved for the treatment of relapsed or refractory Mantle Cell Lymphoma (MCL) and, in 2014, for previously untreated MCL. BTZ has been extensively studied either alone or in combination with other drugs for the treatment of different liquid tumors especially in MM. However, limited data evaluated the efficacy and safety of using BTZ in patients with solid tumors. In this review, we will discuss the advanced and novel mechanisms of action of BTZ documented in MM, solid tumors and liquid tumors. Moreover, we will shed the light on the newly discovered pharmacological effects of BTZ in other prevalent diseases.

    Original languageBritish English
    Pages (from-to)146-168
    Number of pages23
    JournalEXCLI Journal
    Volume22
    DOIs
    StatePublished - 2023

    Keywords

    • Bortezomib
    • liquid tumors
    • multiple myeloma
    • proteasome inhibitor
    • solid tumors

    Fingerprint

    Dive into the research topics of 'BORTEZOMIB ADVANCED MECHANISMS OF ACTION IN MULTIPLE MYELOMA, SOLID AND LIQUID TUMORS ALONG WITH ITS NOVEL THERAPEUTIC APPLICATIONS'. Together they form a unique fingerprint.

    Cite this